Evidence map›Paper›PMID 40515958›Full record

ReviewMolecular and cellular biochemistry2025

Updated insights on ASK1 signaling: mechanisms, regulation, and therapeutic potential in diseases.

Divyanshi Thakur, Aniket Nandi, Yash Kumar Gaur, Karthikeyan Chandrabose, Digambar Kumar Waiker, Ghanshyam Das Gupta, Kalicharan Sharma

Erratum issuedAbstract readReview
PubMed Publisher
In one paragraph

Review in Molecular and cellular biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Divyanshi ThakurDepartment of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga, Punjab, 142001, India.
Aniket NandiDepartment of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga, Punjab, 142001, India.
Yash Kumar GaurDepartment of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga, Punjab, 142001, India.
Karthikeyan ChandraboseDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Digambar Kumar WaikerDepartment of Medicinal Chemistry, Purdue University, West Lafayette, USA.
Ghanshyam Das GuptaDepartment of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga, Punjab, 142001, India.
Kalicharan SharmaDepartment of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga, Punjab, 142001, India. sharmakcpt@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Apoptosis signal-regulating kinase 1 (ASK1) is a serine-threonine kinase, that is a member of the mitogen-activated protein kinase kinase (MAP3K) family, which is expressed or incorporated in nucleated cells which leads to the activation of multiple mitogen-activated protein kinases (MAPK) to regulate cell stress, tumour necrosis factor-α (TNF-α) ligand, lipopolysaccharides and apoptosis. ASK1 gets activated by the ROS, oxidative stress, endoplasmic stress (ER) and various inflammatory cytokines. Dysregulation of ASK1 can lead to various diseases like neurodegenerative disease, cardiovascular disease, cancer, and various other metabolic diseases such as diabetes. This review summarizes ASK1's structure, its family, regulation, and its dual role in disease, highlighting its therapeutic potential for oxidative stress and inflammation-driven conditions while emphasizing the need for further clinical research. Inhibition of ASK1 demonstrates promising potential in treating fibrosis and various other diseases. We also discuss the dual role of ASK1 in both cancer initiation and suppression. Additionally, we explore ASK1 as a therapeutic target in diseases driven by oxidative stress and inflammation, emphasizing the need for further research to support its clinical translation.

Indexed as

Cardiovascular DiseasesInflammationMAP Kinase Kinase Kinase 5Neoplasm ProteinsNeoplasmsNeurodegenerative DiseasesOxidative StressSignal TransductionAnimalsHumansMAP3K5 protein, humanMAP Kinase Kinase Kinase 5Neoplasm ProteinsASK1ASK2ASK3ASK SignalosomeCancerDown regulatorsEtcFibrosisMAPKStructural architectUp regulators

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.